The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.
The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.
The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.
The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.
A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.
The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
The user experienced side effects from finasteride and found improved mood and performance with DHT, but it worsened hair loss. They are considering options like TRT, HCG, and topical treatments like Saw Palmetto, but struggle with balancing hair preservation and functionality.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
User is considering switching from finasteride to dutasteride and adding pyrilutamide for hair loss treatment. Other users recommend dutasteride for its effectiveness and suggest adding pyrilutamide.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.
A user convinced their dad to start using Minoxidil two months ago and Finasteride one month ago for hair regrowth. The dad is showing significant progress, and there are suggestions to add derma stamping for better results.
The user is using Finasteride gel and considering adding Redensyl to their routine, along with weekly microneedling, but is hesitant to use Minoxidil due to its initial shedding phase. They seek advice on the safety and ideal routine for combining these treatments.
The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.